Surgical oncology

City of Hope Opens First U.S. Multicenter Clinical Trial for Robotic Single-Port Mastectomies for Breast Cancer Patients

Retrieved on: 
Tuesday, October 3, 2023
Technology, Health, Women, Oncology, Robotics, Health Technology, Research, Surgery, Consumer, Science, Clinical Trials, Surgical oncology, City of Hope, Surgeon, Clinical trial, Cancer, Lead, Food and Drug Administration Amendments Act of 2007, Urology, Patient, Surgical Innovation, Food, Intuition, Breast cancer, Birth control, City, Hope

City of Hope, one of the largest cancer research and treatment organizations in the United States, is opening a multicenter clinical trial to evaluate the efficacy of robotic-assisted, single-incision mastectomies.

Key Points: 
  • City of Hope, one of the largest cancer research and treatment organizations in the United States, is opening a multicenter clinical trial to evaluate the efficacy of robotic-assisted, single-incision mastectomies.
  • “City of Hope is once again taking the lead in investigating innovations, treatments and therapies that are making big leaps forward for patients with cancer.
  • “City of Hope offers the most advanced breast cancer treatments,” said Jamie Rand , M.D., a breast cancer surgeon at City of Hope and subinvestigator on the clinical trial.
  • Surgeons at City of Hope, a leader in robotic surgery , have performed more than 16,000 nonmastectomy robotic procedures.

Menarini Silicon Biosystems announces new study results on use of CELLSEARCH® liquid biopsy for earlier detection of relapse and to help inform decisions on patient management in stage III Melanoma

Retrieved on: 
Tuesday, October 3, 2023
CT, Surgical oncology, University, Blood, Prevalence, Glomus tumor, Monroe Dunaway Anderson, MD Anderson Cancer Center, Chinese, Trial of the century, Silicon, MRI, CTC, HIV disease progression rates, MD, Patient, Risk, Melanoma, PET/CT, Diagnosis, Recurrence, III, Disease, Medical imaging, Cancer

BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Oct. 3, 2023 /PRNewswire/ -- Menarini Silicon Biosystems, a pioneer of liquid biopsy technology, announced today the publication, in the peer-reviewed journal Cancers, of the results of a clinical study on the utility of CTCs to detect disease relapse substantially earlier than what is currently possible with routine surveillance imaging, in patients with stage III melanoma. This study included 325 patients who were mainly enrolled upon diagnosis of their stage III melanoma status. Blood was collected at different time points to detect CTCs and results were compared with follow-up imaging, to detect disease recurrence. The Menarini Silicon Biosystems CELLSEARCH system and Celltracks® Circulating Melanoma Cell Kit* were used to analyze and enumerate CTCs.

Key Points: 
  • This study included 325 patients who were mainly enrolled upon diagnosis of their stage III melanoma status.
  • Blood was collected at different time points to detect CTCs and results were compared with follow-up imaging, to detect disease recurrence.
  • The Menarini Silicon Biosystems CELLSEARCH system and Celltracks® Circulating Melanoma Cell Kit* were used to analyze and enumerate CTCs.
  • This data suggests that a blood biomarker is now able to help assess which patients with melanoma are most at risk of experiencing a relapse.

Menarini Silicon Biosystems announces new study results on use of CELLSEARCH® liquid biopsy for earlier detection of relapse and to help inform decisions on patient management in stage III Melanoma

Retrieved on: 
Tuesday, October 3, 2023
CT, Surgical oncology, University, Blood, Prevalence, Glomus tumor, Monroe Dunaway Anderson, MD Anderson Cancer Center, Chinese, Trial of the century, Silicon, MRI, CTC, HIV disease progression rates, MD, Patient, Risk, Melanoma, PET/CT, Diagnosis, Recurrence, III, Disease, Medical imaging, Cancer

BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Oct. 3, 2023 /PRNewswire/ -- Menarini Silicon Biosystems, a pioneer of liquid biopsy technology, announced today the publication, in the peer-reviewed journal Cancers, of the results of a clinical study on the utility of CTCs to detect disease relapse substantially earlier than what is currently possible with routine surveillance imaging, in patients with stage III melanoma. This study included 325 patients who were mainly enrolled upon diagnosis of their stage III melanoma status. Blood was collected at different time points to detect CTCs and results were compared with follow-up imaging, to detect disease recurrence. The Menarini Silicon Biosystems CELLSEARCH system and Celltracks® Circulating Melanoma Cell Kit* were used to analyze and enumerate CTCs.

Key Points: 
  • This study included 325 patients who were mainly enrolled upon diagnosis of their stage III melanoma status.
  • Blood was collected at different time points to detect CTCs and results were compared with follow-up imaging, to detect disease recurrence.
  • The Menarini Silicon Biosystems CELLSEARCH system and Celltracks® Circulating Melanoma Cell Kit* were used to analyze and enumerate CTCs.
  • This data suggests that a blood biomarker is now able to help assess which patients with melanoma are most at risk of experiencing a relapse.

New State-Of-The-Art Patient Building Opens at Providence Cedars-Sinai Tarzana Medical Center

Retrieved on: 
Monday, October 2, 2023
Heart, CT, Donald Friese, LEED, Pharmacy, Privacy, San Fernando Valley, Silver, Certification, Surgical oncology, Neuroscience, Patient, Nature, Physician, Tupella Family Tower House, Adolescence, McCarthy, Health, Family, Perkins, Caregiver, Hospital, Nursing, Medical imaging, Cedars-Sinai Medical Center

TARZANA, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Providence Cedars-Sinai Tarzana Medical Center has opened its new patient tower, the centerpiece of an extensive and ongoing hospital expansion and modernization plan.

Key Points: 
  • TARZANA, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Providence Cedars-Sinai Tarzana Medical Center has opened its new patient tower, the centerpiece of an extensive and ongoing hospital expansion and modernization plan.
  • “The Friese Family Tower marks the beginning of a new era of health care in the San Fernando Valley,” said Nick Lymberopoulos, chief executive at Providence Cedars-Sinai Tarzana Medical Center.
  • “The McCarthy Building Companies team is proud to be part of the Tarzana Reimagined project,” said Erik Chessmore, vice president, operations at McCarthy.
  • “We are forever grateful to the Friese family and honored they chose to invest in our community through Providence Cedars-Sinai Tarzana Medical Center,” said Matthew Rinnert, the hospital foundation’s chief philanthropy officer.

New Neoadjuvant Trial Confirms the Predictive Utility of MammaPrint® + BluePrint®

Retrieved on: 
Thursday, September 28, 2023
Blueprint, Lymphedema, Surgical oncology, Neoadjuvant therapy, NCT, Neoplasm, Cancer, Woman, Breast, Gene expression profiling, MS, MINT, TAD, Annals of Surgical Oncology, MD, Patient, Lymph, Risk, Rollcage Stage II, Health, III, Breast cancer, Medical imaging, MammaPrint

IRVINE, Calif. & AMSTERDAM, Sept. 28, 2023 /PRNewswire/ -- Agendia®, Inc., a global leader in innovative genomic technology and diagnostic tests, announced today the publication of the Multi-Institutional Neoadjuvant Therapy MammaPrint Project I (MINT) trial, a prospective study designed to evaluate the utility of molecular profiling alongside traditional pathologic and clinical prognostic factors in predicting the response to neoadjuvant chemotherapy (NCT) in patients with locally advanced breast cancer (LABC).

Key Points: 
  • This is the first neoadjuvant study to show that nodal downstaging in response to neoadjuvant therapy can be predicted by MammaPrint + BluePrint, Agendia's advanced genomic assays.
  • The MINT trial represents a collaboration of leading institutions and researchers dedicated to advancing breast cancer treatment.
  • It reaffirms the commitment of the scientific and medical communities to improve patient care and outcomes through cutting-edge research.
  • For more information about Agendia, visit www.agendia.com and follow Agendia on Facebook , Twitter ,  and LinkedIn .

Montefiore Einstein Comprehensive Cancer Center Unveils New Destination for Breast Care

Retrieved on: 
Thursday, September 28, 2023
Albert Einstein College of Medicine, BOLD, GE HealthCare, Lymphedema, Surgical oncology, Radiation, Surgeon, Hair loss, 3D, Clinical trial, GE, Woman, Research, Element, Anesthesia, Genetic counseling, Incidence, Montefiore, Breast, Patient, Physician, Head, Diagnosis, Health, Mammography, Breast cancer, Medical imaging, Birth control, Pharmaceutical industry, Radiology

BRONX, N.Y., Sept. 28, 2023 /PRNewswire/ -- Yesterday, Montefiore Einstein Comprehensive Cancer Center (MECCC) opened a new state-of-the-art breast center at the Hutchinson Metro Center at 1250 Waters Place. The center is home to some of the nation's top breast cancer physicians, surgeons and researchers. It offers screening studies, advanced imaging, minimally invasive surgery, plastic & reconstructive surgery, a high-risk breast cancer prevention and lymphedema prevention program, as well as genetic counseling under one roof. Services like medical & radiation oncology, nutrition, and access to MECCC's Bronx Oncology Living Daily (BOLD) wellness and support program, are also available. The goal of the breast center is to provide every patient with an unparalleled level of evaluation and care.

Key Points: 
  • Comprehensive Breast Services & the Most Advanced Technology Available in a New, Healing Environment
    BRONX, N.Y., Sept. 28, 2023 /PRNewswire/ -- Yesterday, Montefiore Einstein Comprehensive Cancer Center (MECCC) opened a new state-of-the-art breast center at the Hutchinson Metro Center at 1250 Waters Place.
  • The center is home to some of the nation's top breast cancer physicians, surgeons and researchers.
  • The goal of the breast center is to provide every patient with an unparalleled level of evaluation and care.
  • For more information about the breast center and MECCC's research and patient care, including its High-Risk Prevention and Surveillance program, visit cancer.montefioreeinstein.org.

Nonprofit Raises $775,000 to End Pancreatic Cancer

Retrieved on: 
Wednesday, September 13, 2023
Other Education, Education, Oncology, General Health, Women, Philanthropy, Genetics, Clinical Trials, Fund Raising, Foundation, Family, Science, Other Philanthropy, Consumer, Research, Health, Pancreatic cancer, Survivor, Darkness, Translational Genomics Research Institute, City of Hope, Jenna, Light, Hope, Column, Illumination, Cancer, Grief, Surgical oncology, City, Patient, Physician, Diagnosis, Pansy, Applebee's, Conference, Disease, Pharmaceutical industry

Since its inception in 2009, Purple Pansies has remained steadfast in its commitment to allocate 100% of all funds raised, minus expenses, towards combating pancreatic cancer.

Key Points: 
  • Since its inception in 2009, Purple Pansies has remained steadfast in its commitment to allocate 100% of all funds raised, minus expenses, towards combating pancreatic cancer.
  • Founder Maria Fundora, driven by the heartbreaking loss of her mother to pancreatic cancer just three months after diagnosis, has transformed her grief into unwavering determination.
  • This year’s theme, "Illumination," was to recognize the need for light and hope in the darkness that is pancreatic cancer and a nod to the origins of Purple Pansies.
  • Recognizing the growing urgency, Purple Pansies joined forces with the Translational Genomics Research Institute (TGen), a division of City of Hope, a nonprofit medical research institute dedicated to pioneering strategies targeting pancreatic cancer.

Phase 2 Data Demonstrate Potential of Vergent Biosciences’ Tumor-Targeted Fluorescent Imaging Agent to Improve Success of Lung Cancer Surgeries

Retrieved on: 
Monday, September 11, 2023
Oncology, Health, Other Health, Other Science, Research, Science, Biotechnology, Adenocarcinoma, Surgical oncology, Surgeon, Neoplasm, Carcinoid, Pathology, Cancer, Lung cancer, Lung, Patient, Lymph, Carcinoma, Hospital, Conference, NIR, Safety, Medical imaging

Findings from the Phase 2 surgical study evaluating VGT-309 suggest the investigational agent could improve surgeons’ ability to see difficult-to-find and previously undetected tumors in real time to help optimize patient outcomes.

Key Points: 
  • Findings from the Phase 2 surgical study evaluating VGT-309 suggest the investigational agent could improve surgeons’ ability to see difficult-to-find and previously undetected tumors in real time to help optimize patient outcomes.
  • Each patient in the study received a VGT-309 infusion on the day prior to or day of surgery.
  • Of the 27 participants, 23 had confirmed cancer, one had typical carcinoid, and three had non-neoplastic processes.
  • “We look forward to expanding on these results in future studies including our upcoming multi-center Phase 2 clinical trial.”

Convergent Therapeutics Expands Leadership Team with the Appointments of Neil Bander, MD. as Chief Scientific Officer, Eric M. Sullivan as Chief Financial Officer, and Dimitris Voliotis, MD. as Senior Vice President of Clinical Development

Retrieved on: 
Wednesday, September 6, 2023
Prostate Cancer Foundation, Surgical oncology, Royal college, Society, Immunoconjugate, Therapy, Prostate cancer, PSMA, Convergent, Drug, Bayer, Cancer, Radiopharmaceutical, Triplet, Eisai, Surgical Innovation, MD, Patient, Gemini, Weill Cornell Medicine, CFO, Growth, Merrimack Pharmaceuticals, Pharmaceutical industry

These appointments follow the company's recent closing of a $90 million Series A financing round to develop radiopharmaceuticals to treat cancer.

Key Points: 
  • These appointments follow the company's recent closing of a $90 million Series A financing round to develop radiopharmaceuticals to treat cancer.
  • "With our strong financial backing, we are poised to accelerate the clinical development of our lead asset CONV01-a to transform the lives of patients suffering with prostate cancer."
  • Over the past 25 years, Dr. Bander pioneered the development of PSMA-targeted imaging agents and therapeutics, transforming the prostate cancer landscape.
  • Dr. Voliotis is joining Convergent from Zentalis Pharmaceuticals, where he was Senior Vice President & Head of Global Development.

National Cancer Institute (NCI) Director, Monica M. Bertagnolli, M.D., Selected as Recipient of the 2023 AIM-HI Beacon Award for Women Leaders in Oncology

Retrieved on: 
Wednesday, August 16, 2023
Research, Women, Public Policy, Government, Philanthropy, White House, Federal Government, Consumer, Health, Foundation, Science, Oncology, National Foundation for Cancer Research, Survivor, Entrepreneurship, Drug development, University, Therapy, Women Leaders in Global Health Conference, Gastrointestinal cancer, AoC Beacon Awards, National Press Club (United States), Cancer, Quality of life, Biomedical Research, Press club, Woman, University of California, San Diego, Harvard Medical School, National Cancer Institute, Surgical oncology, Patient, Arizona State University, Bertagnolli, Diagnosis, NFCR, Director of the National Institutes of Health, Empathy, Complex adaptive system, NCI, NIH, Dana–Farber Cancer Institute, Pharmaceutical industry, Nursing, Management, Immunocore, Brigham

The AIM-HI Accelerator Fund (AIM-HI) today announced the recipient of the 2023 AIM-HI Beacon Award for Women Leaders in Oncology as Monica M. Bertagnolli, M.D., Director of the National Cancer Institute (NCI) .

Key Points: 
  • The AIM-HI Accelerator Fund (AIM-HI) today announced the recipient of the 2023 AIM-HI Beacon Award for Women Leaders in Oncology as Monica M. Bertagnolli, M.D., Director of the National Cancer Institute (NCI) .
  • The Beacon Award for Women Leaders in Oncology was established in 2022 by the AIM-HI Accelerator Fund, a translational research and impact-investment affiliate of the National Foundation for Cancer Research (NFCR).
  • Dr. Bertagnolli will be honored as the 2023 AIM-HI Beacon Award recipient at a luncheon ceremony at the National Press Club in Washington, D.C., on October 21, 2023.
  • Tickets to attend the 2023 Global Summit and Award Ceremonies for Cancer Research and Entrepreneurship are now open for purchase.